A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIs

A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIs - A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIs

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003263

Enrollment

Registered

2010-02-27

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous Non-small-cell Lung Cancer

Interventions

Carboplatin AUC 5 or 6 day 1+Paclitaxel 200mg/m2 day 1+Bevacizumab 15 mg/kg day 1 q3w 3-6 cycles followed by Bevacizumab 15 mg/kg day 1 q3w until disease progression

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically proven non-squamous non-small cell lung cancer 2)Non-squamous non-small cell lung cancer harboring mutations of EGFR patients with stage IIIB,stage IV (UICC-7) or recurrent disease after surgery,who have previously treated EGFR-TKIs 3)With measurable lesion(RECIST version 1.1) 4)More than 1 week after the last EGFR-TKIs 5)If the patient underwent therapy, there should be the following interval between the therapy and the registration i)Radiotherapy other than thoracic radiation ->1 week ii)Radiotherapy including pulmonary field ->3 months iii)Surgery(except CV-port reservation) ->4 weeks iv)Thoracic drainarge ->2 weeks v)Open biopsy, treatment of injury ->2 weeks vi)Aspiration biopsy, CV-port reservation ->1 week 6)Age: 20-74 years old 7)ECOG PS 0-1 8)Adequate organ function 9)Life expectancy more than 3 months 10)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Interstitial pneumonia or pulmonary fibrosis detectable on CT scan 2)History of drug induced interstitial pneumonia 3)History of severe drug allergy 4)History of active infection or other serious disease condition (GI bleeding,etc.) 5)History of poorly controlled pleural effusion,pericardial effusion and ascites 6)History of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris,herat failure,etc.) 7)Uncontrollable hypertension 8)Uncontrollable diabetes mellitus 9)Current or previous history of hemoptysis or hemosputum 10)Current or previous (within the last 1 year) history of cerebrovascular disease 11)Current or previous (within the last 1 year) history of GI perforation 12)Symptomatic brain metastasis 13)Traumatic fracture of unrecovery 14)The operation has been scheduled for the examination period 15)Tumor invasive to the chest large blood vessel. Cavity in brain or lung tumor. 16)Evidence of bleeding diathesis or coagulopathy 17)Thrombosis that need to treat 18)History of active double cancer 19)History of active psychological disease 20)History of pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Overall survival Progression free survival Disease control rate Adverse events	—

Countries

Japan

Contacts

Public ContactYoshihiro Hattori

Hyogo Cancer Center Department of Thoracic Oncology

hattori@hp.pref.hyogo.jp078-929-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026